Diagnostic and Prognostic Biomarkers of Disease Status and Response to Therapy in Glioma

M.D. Anderson Cancer Center, “Multigene Predictors of Outcome in Glioblastoma.”

The Mayo Clinic, “Cadherins and Catenins as Biomarkers of Pediatric and Adult Glioma Aggressiveness.”

Northwestern University, “Predicting the Therapy Response of High-Grade Gliomas Based on a Network of Endogenous Modulators of Nuclear Factor-kappaB.”

Mount Sinai Medical Center, “Standardization of Perfusion MR Imaging and Predicting Clinical Outcome in Patients with Gliomas Using Perfusion MR Metrics in a Multi-Institutional Setting.”

Development of Molecularly Targeted Therapeutics for Brain Cancer

Dana Farber, “Inhibition of ATM and CHK2 as Treatment for Glioblastoma Multiforme.”

Johns Hopkins University, “Depleting Cancer Stem Cells by Notch Pathway Blockade in Glioblastomas."

The Wistar Institute, “Development of MicroRNA Inhibitors for the Treatment of Glioblastomas.”

Case Western Reserve University, “Efficacy of PPARg Agonists in Treatment of Glioma."

Duke University Medical Center, “RNA Loaded Dendritic Cell Vaccines Targeting Brain Tumor Stem Cells During Hematopoietic Recovery from Temozolomide-induced Lymphopenia.”

The Salk Institute for Biological Studies, “Novel Therapies for Glioblastoma."

M.D. Anderson Cancer Center, “Identification of Compensatory Molecular Pathways Using Functional Genomic and Synthetic Lethality Screening in Glioblastoma Treated with PI3K Inhibitors.”

Co-funded with the Tug McGraw Foundation

University of California San Francisco, “Evolution of a Hypomethylated and Hyperproliferative Phenotype in Glioblastoma Multiforme (GBM) and its Reversal by a High Methyl-donor Regimen.”